|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Biomedical Science, University of Sheffield, Sheffield, England, United Kingdom
2 Department of Anatomy, University of Bristol, Bristol, England, United Kingdom
3 Mammalian Genetics of Disease Unit, University of Sheffield, Sheffield, England, United Kingdom
4 Department of Anatomy, Zagreb University School of Medicine, Zagreb, Croatia
5 MRC Mary Lyon Centre, Didcot, England, United Kingdom
6 GlaxoSmithKline Pharmaceuticals, England, United Kingdom
7 Mammalian Genetics Unit, MRC Harwell, Didcot, United Kingdom
* To whom correspondence should be addressed. E-mail: I.Barbaric{at}sheffield.ac.uk.
The mechanisms that regulate bone mass are important in a variety of complex diseases such as osteopenia and osteoporosis. Regulation of bone mass is a polygenic trait and is also influenced by various environmental and lifestyle factors, making analysis of the genetic basis difficult. As an effort towards identifying novel genes involved in regulation of bone mass, ENU mutagenesis in mice has been utilised. Here we describe a mouse mutant termed Yoda that was identified in an ENU mutagenesis screen for dominantly acting mutations. Mice heterozygous for the Yoda mutation exhibit craniofacial abnormalities - shortened snouts, wider skulls and deformed nasal bones, underlined by altered morphology of frontonasal sutures and failure of interfrontal suture to close. A major feature of the mutant is reduced bone mineral density. Homozygosity for the mutation results in embryonic lethality. Positional cloning of the locus identified a missense mutation in a highly conserved region of the ankyrin repeat domain 11 gene (Ankrd11). This gene has not been previously associated with bone metabolism and, thus, identifies a novel genetic regulator of bone homeostasis.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |